Drug Trial Radar · NCT00052377
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Last checked: Nov 20, 2026Latest source record: Jan 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
46
Actual
Start
Sep 2002
Primary completion
Jun 2005
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I/II trial to study the effectiveness of combining interleukin-12 with interleukin-2 in treating patients who have mycosis fungoides. Biological therapies, such as interleukin-12 and interleukin-2, use different ways to stimulate the immune system and stop cancer cells from growing. Combining more than one biological therapy may kill more tumor cells
Conditions
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage I Mycosis Fungoides/Sezary Syndrome
- Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage II Mycosis Fungoides/Sezary Syndrome
- Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage III Mycosis Fungoides/Sezary Syndrome
- Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions
aldesleukinBiological
Given SC
recombinant interleukin-12Biological
Given SC
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response rate defined as the percentage of patients who achieve complete or partial response (Phase I)Time frame: Up to week 13
- Refractory disease defined as a patient who initially shows clinical improvement in the early weeks of treatment and then exhibits a response plateau for >= 30 days or exhibits progression of their disease (Phase I)Time frame: Up to week 13
- Improved clinical response defined as a patient who had refractory or persistent disease and who subsequently had a >= 25% clinical improvement for >= 30 days during aldesleukin and recombinant interleukin-12 therapy (Phase II)Time frame: Up to week 25
- Toxicities graded using National Cancer Institute (NCI) Common Toxicity Criteria Version 2.0 (Phase I)Time frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.